Business Context and Reporting Period
Veracyte, Inc. filed a Current Report on Form 8-K dated April 28, 2015, reporting the completion of a private placement of equity securities. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Key Financial Metrics
- Transaction Type: Private placement of 4,907,975 shares of common stock.
- Purchase Price: $8.15 per share.
- Gross Proceeds: Approximately $40 million.
- Placement Agent Fees: Approximately $2.5 million (paid to Piper Jaffray & Co. and William Blair & Company, L.L.C.).
- Net Proceeds: Approximately $37.3 million after deducting fees and expenses.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in share count and capitalization resulting from the issuance of nearly 4.91 million new shares to accredited investors. This transaction was executed pursuant to a Securities Purchase Agreement and a Registration Rights Agreement dated April 22, 2015.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The shares issued were sold in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933 and have not been registered for public resale, though the company agreed to register them for resale under the Registration Rights Agreement.
Investor Verification Checklist
- Verify the final net proceeds received by the company after all transaction expenses.
- Confirm the dilution impact of the 4,907,975 new shares on existing shareholders.
- Review the Registration Rights Agreement to understand the timeline for when these shares may be resold in the public market.
- Check subsequent filings for the intended use of the approximately $37.3 million in net proceeds.